The Effect of Nitroglycerine on Microcirculatory Abnormalities During Sepsis (NISMIS)

This study has been completed.
Sponsor:
Information provided by:
Medical Centre Leeuwarden
ClinicalTrials.gov Identifier:
NCT00493415
First received: June 27, 2007
Last updated: July 15, 2008
Last verified: July 2008
  Purpose

The purpose of this study is to evaluate the effect of nitro-glycerine on the microcirculation (smallest vessel type) in patients with severe sepsis and septic shock.

Nitro-glycerine is a well known medicine in cardiology and is used to improve circulation. In this ICU the investigators use nitro-glycerine to improve the organ perfusion; but it's no common therapy in the rest of the world. The investigators now compare nitro-glycerine and placebo by looking to the sublingual microcirculation by a small camera (SDF imaging).


Condition Intervention Phase
Sepsis
Septic Shock
Drug: nitroglycerin iv
Drug: placebo = nacl 0.9%
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Evaluation of the Effect of Nitroglycerine Versus Placebo on the Microcirculation by Means of SDF Imaging in Septic Patients on the ICU

Resource links provided by NLM:


Further study details as provided by Medical Centre Leeuwarden:

Primary Outcome Measures:
  • increase of MFI by nitro-glycerine [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • decrease of length of stay decrease of SOFA decrease of morbidity/mortality [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 70
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
nitroglycerine iv
Drug: nitroglycerin iv
loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
Other Name: nitropohl
Placebo Comparator: 2
nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
Drug: placebo = nacl 0.9%
4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
Other Name: isotonic saline

Detailed Description:

This study starts at admission of the patient on the ICU. In the next 24 hours the patient receives nitro-glycerine or placebo (randomised). At time = 0, ½, 2, 12 and 24 hour we evaluate the microcirculation by SDF imaging and monitoring of hemodynamic parameters.

Informed consent is obtained of the relatives.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Severe sepsis
  • Proven infection
  • Informed consent

Exclusion Criteria:

  • Age < 18 years
  • Pregnancy
  • Use of nitroglycerine within 24 hours prior to ICU admittance
  • Necessity to use nitroglycerine iv for instable angina
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00493415

Locations
Netherlands
Medical Centre Leeuwarden - Intensive Care Unit
Leeuwarden, Netherlands, 8901 BR
Sponsors and Collaborators
Medical Centre Leeuwarden
Investigators
Principal Investigator: E C Boerma, MD Medical Centre Leeuwarden
  More Information

No publications provided by Medical Centre Leeuwarden

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: EC Boerma, Medical Center Leeuwarden
ClinicalTrials.gov Identifier: NCT00493415     History of Changes
Other Study ID Numbers: TPO 436, ABR 12558, Eudract 2006-004298-88, CCMO NL12558.099.06
Study First Received: June 27, 2007
Last Updated: July 15, 2008
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Medical Centre Leeuwarden:
microcirculation
sepsis
nitroglycerine
SDF imaging

Additional relevant MeSH terms:
Sepsis
Shock, Septic
Toxemia
Infection
Inflammation
Pathologic Processes
Shock
Systemic Inflammatory Response Syndrome
Nitroglycerin
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on October 20, 2014